ABBV vs. TECH: AbbVie vs. Bio-Techne Stock Comparison

November 11, 2026

How do AbbVie (ABBV) and Bio-Techne (TECH) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

AbbVie (ABBV) and Bio-Techne (TECH) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but ABBV is classified in Biotechnology while TECH is classified in Life Sciences Tools & Services.

Company profile comparison for AbbVie (ABBV) and Bio-Techne (TECH)
Profile Item	ABBV	TECH
Name	AbbVie Inc.	Bio-Techne Corp.
Country/Region	United States	United States
GICS Sector	Health Care	Health Care
GICS Industry Group	Pharmaceuticals, Biotechnology & Life Sciences	Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry	Biotechnology	Life Sciences Tools & Services
GICS Sub-Industry	Biotechnology	Life Sciences Tools & Services
Market Capitalization	514.92 billion USD	11.43 billion USD
Currency	USD	USD
Exchange	NYSE	Nasdaq
Listing Date	January 2, 2013	February 9, 1989
Security Type	Common Stock	Common Stock

Price Performance

Cumulative Growth

ABBV

TECH

GSPC

AbbVie (ABBV) vs. Bio-Techne (TECH), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…

Trailing total returns for AbbVie (ABBV) and Bio-Techne (TECH). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…

Calendar-year total returns for AbbVie (ABBV) and Bio-Techne (TECH). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for AbbVie (ABBV) and Bio-Techne (TECH)
Metric	ABBV	TECH
Total Return (1Y)	37.33%	27.56%
Total Return (3Y, Annualized)	32.74%	9.11%
Total Return (5Y, Annualized)	24.73%	-9.91%

Risk Profile

Drawdown History

ABBV

TECH

GSPC

AbbVie (ABBV) vs. Bio-Techne (TECH), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…

Distribution of monthly total returns for AbbVie (ABBV) and Bio-Techne (TECH). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for AbbVie (ABBV) and Bio-Techne (TECH)
Metric	ABBV	TECH
Volatility (1Y, Annualized)	25.65%	43.08%
Beta (5Y)	0.21	1.26
Max Drawdown (5Y)	-21.92%	-65.87%
Avg. Volume (3M)	4.76M	2.81M

Risk-Adjusted Performance

Risk-Return Positioning

ABBV and TECH are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for AbbVie (ABBV) and Bio-Techne (TECH)
Metric	ABBV	TECH
Sharpe Ratio (1Y)	1.29	0.54
Sortino Ratio (1Y)	2.02	0.82

Profitability

ROE (TTM)

Capital efficiency shows on one side only: Bio-Techne (TECH) earns 8.33% on shareholders’ equity, ranked against its industry; AbbVie (ABBV) has no ROE this period.

ABBV

Pharmaceuticals, Biotechnology & Life Sciences industry group

Max: 109.18%
Q3: 6.23%
Median: -26.66%
Q1: -64.05%
Min: -167.77%
ABBV: --

TECH

Pharmaceuticals, Biotechnology & Life Sciences industry group

8.33%

Max: 109.18%
TECH: 8.33%
Q3: 6.23%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

AbbVie (ABBV) vs. Bio-Techne (TECH): ABBV does not report ROE, so it has no value marker; TECH is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

Net Margin (TTM)

For every dollar of sales, both AbbVie (ABBV) at 15.67% and Bio-Techne (TECH) at 14.00% retain more as net profit than most peers, landing in the top net margin quartile of their industries.

ABBV

Pharmaceuticals, Biotechnology & Life Sciences industry group

15.67%

Max: 18.05%
ABBV: 15.67%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

TECH

Pharmaceuticals, Biotechnology & Life Sciences industry group

14.00%

Max: 18.05%
TECH: 14.00%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

AbbVie (ABBV) vs. Bio-Techne (TECH): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

AbbVie (ABBV) at 39.59% operates in the top operating margin quartile, ahead of Bio-Techne (TECH) at 12.21%, which runs around its industry’s norm.

ABBV

Pharmaceuticals, Biotechnology & Life Sciences industry group

39.59%

Max: 83.12%
ABBV: 39.59%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

TECH

Pharmaceuticals, Biotechnology & Life Sciences industry group

12.21%

Max: 83.12%
Q3: 14.77%
TECH: 12.21%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

AbbVie (ABBV) vs. Bio-Techne (TECH): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for AbbVie (ABBV) and Bio-Techne (TECH)
Metric	ABBV	TECH
ROE (TTM)	--	8.33%
ROA (TTM)	10.74%	6.38%
Net Margin (TTM)	15.67%	14.00%
Operating Margin (TTM)	39.59%	12.21%
Gross Margin (TTM)	73.72%	66.23%

Growth

Revenue Growth

Both AbbVie (ABBV) at 8.57% and Bio-Techne (TECH) at -0.38% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

AbbVie (ABBV) vs. Bio-Techne (TECH): A comparison of their Revenue Growth across different time periods.

EPS Growth

Bio-Techne (TECH) at 152.17% sits in the top EPS growth quartile, while AbbVie (ABBV) at -0.84% is closer to the peer norm — faster per-share earnings growth for TECH.

AbbVie (ABBV) vs. Bio-Techne (TECH): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for AbbVie (ABBV) and Bio-Techne (TECH)
Metric	ABBV	TECH
Revenue Growth (YoY)	8.57%	-0.38%
Revenue Growth (3Y CAGR)	1.75%	2.25%
EPS Growth (YoY)	-0.84%	152.17%
EPS Growth (3Y CAGR)	-29.03%	-12.97%

Financial Strength

Current Ratio (MRQ)

Both AbbVie (ABBV) at 0.87 and Bio-Techne (TECH) at 2.28 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.

ABBV

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.87

Max: 25.13
Q3: 12.13
Median: 5.52
Q1: 2.47
ABBV: 0.87
Min: 0.10

TECH

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.28

Max: 25.13
Q3: 12.13
Median: 5.52
Q1: 2.47
TECH: 2.28
Min: 0.10

AbbVie (ABBV) vs. Bio-Techne (TECH): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Only one side’s leverage can be read here: Bio-Techne (TECH) carries debt-to-equity ratio of 0.13 against its industry range, while AbbVie (ABBV) reports no figure this period.

ABBV

Pharmaceuticals, Biotechnology & Life Sciences industry group

Max: 1.42
Q3: 0.65
Median: 0.15
Q1: 0.02
Min: 0.00
ABBV: --

TECH

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.13

Max: 1.42
Q3: 0.65
Median: 0.15
TECH: 0.13
Q1: 0.02
Min: 0.00

AbbVie (ABBV) vs. Bio-Techne (TECH): ABBV does not report debt-to-equity ratio, so it has no value marker; TECH is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

Financial Strength Metrics

Financial strength metrics for AbbVie (ABBV) and Bio-Techne (TECH)
Metric	ABBV	TECH
Current Ratio (MRQ)	0.87	2.28
Debt / Equity (MRQ)	--	0.13
Net Debt / EBITDA	2.21	-0.20

Dividends

Dividend Yield (TTM)

Both AbbVie (ABBV) at 2.40% and Bio-Techne (TECH) at 0.44% yield above their industries’ entire benchmark ranges — high enough that dividend safety, not income, becomes the first question.

ABBV

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.40%

ABBV: 2.40%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

TECH

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.44%

TECH: 0.44%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

AbbVie (ABBV) vs. Bio-Techne (TECH): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

AbbVie (ABBV) reports payout ratio above 100% at 117.35%, meaning dividends exceeded current-period earnings and sustainability needs extra context. Meanwhile Bio-Techne (TECH) reports 27.59%, ranking against industry peers normally.

ABBV

Pharmaceuticals, Biotechnology & Life Sciences industry group

117.35%

ABBV: 117.35%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

TECH

Pharmaceuticals, Biotechnology & Life Sciences industry group

27.59%

TECH: 27.59%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

AbbVie (ABBV) vs. Bio-Techne (TECH): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for AbbVie (ABBV) and Bio-Techne (TECH)
Metric	ABBV	TECH
Dividend Yield (TTM)	2.40%	0.44%
Dividend Payout Ratio (TTM)	117.35%	27.59%

Valuation

P/E Ratio (TTM)

Both AbbVie (ABBV) at 50.05 and Bio-Techne (TECH) at 62.74 sit in the richer earnings-multiple quartile for P/E ratio, so investors are paying more for TTM earnings than they pay for typical peers.

ABBV

Pharmaceuticals, Biotechnology & Life Sciences industry group

50.05

Max: 85.34
ABBV: 50.05
Q3: 43.46
Median: 26.69
Q1: 13.30
Min: 0.07

TECH

Pharmaceuticals, Biotechnology & Life Sciences industry group

62.74

Max: 85.34
TECH: 62.74
Q3: 43.46
Median: 26.69
Q1: 13.30
Min: 0.07

AbbVie (ABBV) vs. Bio-Techne (TECH): A comparison of their P/E ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/S Ratio (TTM)

On P/S ratio, both AbbVie (ABBV) at 7.80 and Bio-Techne (TECH) at 9.31 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

ABBV

Pharmaceuticals, Biotechnology & Life Sciences industry group

7.80

Max: 58.18
Q3: 25.77
ABBV: 7.80
Median: 7.30
Q1: 3.01
Min: 0.01

TECH

Pharmaceuticals, Biotechnology & Life Sciences industry group

9.31

Max: 58.18
Q3: 25.77
TECH: 9.31
Median: 7.30
Q1: 3.01
Min: 0.01

AbbVie (ABBV) vs. Bio-Techne (TECH): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

AbbVie (ABBV) reports a negative P/B ratio of -112.34, meaning negative book equity — the multiple itself is not meaningful for valuation. Meanwhile Bio-Techne (TECH) reports 5.28, ranking against industry peers normally.

ABBV

Pharmaceuticals, Biotechnology & Life Sciences industry group

-112.34

Max: 13.53
Q3: 6.54
Median: 3.25
Q1: 1.69
Min: -5.59
ABBV: -112.34

TECH

Pharmaceuticals, Biotechnology & Life Sciences industry group

5.28

Max: 13.53
Q3: 6.54
TECH: 5.28
Median: 3.25
Q1: 1.69
Min: -5.59

AbbVie (ABBV) vs. Bio-Techne (TECH): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for AbbVie (ABBV) and Bio-Techne (TECH)
Metric	ABBV	TECH
P/E Ratio (TTM)	50.05	62.74
P/S Ratio (TTM)	7.80	9.31
P/B Ratio (MRQ)	-112.34	5.28
Free Cash Flow Yield (TTM)	3.44%	2.39%